Binding partners specific for vitamin D epimers

Patent metadata

Field	Value
Publication number	US-9815907-B2
Application number	US-201515319221-A
Country	US
Kind code	B2
Filing date	Jun 22, 2015
Priority date	Jun 27, 2014
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier.

First claim

What is claimed is:

1. A binding partner prepared against a compound of the formula:
(R 1 ) p -(L) q -Z
wherein

Y is O, S, CR, or NR 4 ,
X is —O—(CH 2 ) n —C(O)—, —(CH 2 ) w —C(O)—, —(CH 2 ) w —C(O)—(CH 2 ) x —C(O)—, —(CH 2 ) w —C(O)—NH(CH 2 ) y —C(O)—, or —NR 3 —C(O)—,
R is independently H or alkyl,
R 2 is H,
R 3 and R 4 are independently H or alkyl,
R 5 and R 6 are H,
R 11 is H,
n is an integer from 0 to 10,
w is an integer from 1 to 10,
x is an integer from 1 to 10,
y is an integer from 1 to 10,
p is 1,
L is a linking group,
q is 0 or 1,
Z is an immunogenic carrier; and
wherein said binding partner is an antibody that specifically binds to 3-epi-25-hydroxyvitamin D but does not bind to any detectable degree with 25-hydroxyvitamin D.

2. The binding partner according to claim 1 wherein in the compound

3. The binding partner according to claim 1 wherein in the compound

4. An antibody that is specific for 3-epi-25-hydroxyvitamin D 3 and does not bind to any detectable degree to non-epi-vitamin D compounds, wherein the non-epi-vitamin D compounds are 25-hydroxyvitamin D; calcidiol; 1,25-dihydroxyvitamin D 3 ; 1,25-dihydroxy vitamin D 4 ; 1,25-dihydroxy vitamin D 5 ; and 1,25-dihydroxy vitamin D 6 .

5. A method of separating an epimeric vitamin D from a sample suspected of containing an epimeric vitamin D, the method comprising:
contacting a aqueous medium comprising the sample with an affinity chromatography medium to which is bound an antibody according to claim 4 to capture the epimeric vitamin D, and
separating the aqueous medium from the affinity chromatography medium.

6. The method according to claim 5 further comprising separating the epimeric vitamin D from the affinity chromatography medium.

Assignees

• Siemens Healthcare Diagnostics Inc

Inventors

• Sharma Manoj
• Mareeva Tatiana
• Smirnov Yuriy
• Bedzyk William D
• Teng Zhu
• Wei Tie Quan

Classifications

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K16/26 Primary

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• C07K16/44 Primary

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

• B01D15/3809 Primary

  of the antigen-antibody type, e.g. protein A, G or L chromatography · CPC title

• G01N33/82

  involving vitamins {or their receptors} · CPC title